Article

Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma

Department of Radiation Sciences, Umeå University, Umeå, Västerbotten, Sweden
PLoS Medicine (Impact Factor: 14). 01/2006; 3(1):e13. DOI: 10.1371/journal.pmed.0030013
Source: PubMed

ABSTRACT Conventional renal cell carcinoma (cRCC) accounts for most of the deaths due to kidney cancer. Tumor stage, grade, and patient performance status are used currently to predict survival after surgery. Our goal was to identify gene expression features, using comprehensive gene expression profiling, that correlate with survival.
Gene expression profiles were determined in 177 primary cRCCs using DNA microarrays. Unsupervised hierarchical clustering analysis segregated cRCC into five gene expression subgroups. Expression subgroup was correlated with survival in long-term follow-up and was independent of grade, stage, and performance status. The tumors were then divided evenly into training and test sets that were balanced for grade, stage, performance status, and length of follow-up. A semisupervised learning algorithm (supervised principal components analysis) was applied to identify transcripts whose expression was associated with survival in the training set, and the performance of this gene expression-based survival predictor was assessed using the test set. With this method, we identified 259 genes that accurately predicted disease-specific survival among patients in the independent validation group (p < 0.001). In multivariate analysis, the gene expression predictor was a strong predictor of survival independent of tumor stage, grade, and performance status (p < 0.001).
cRCC displays molecular heterogeneity and can be separated into gene expression subgroups that correlate with survival after surgery. We have identified a set of 259 genes that predict survival after surgery independent of clinical prognostic factors.

Full-text

Available from: Kjell Grankvist, Jun 02, 2015
0 Followers
 · 
164 Views
  • BMC Medicine 12/2015; 13(1). DOI:10.1186/s12916-015-0292-9 · 7.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the prognostic significance of Notch1 activation in patients with clear-cell renal cell carcinoma (ccRCC). We retrospectively enrolled 203 patients with ccRCC undergoing nephrectomy at Zhongshan Hospital of Fudan University between 2003 and 2004. Notch1 activation was assessed by immunohistochemical staining of the intracellular domain of Notch1 (ICN1) in specimens of patients. The Kaplan-Meier method, Cox regression models, and Harrell concordance index (C-index) calculation were used to evaluate the prognostic value of ICN1 expression and its association with clinicopathologic features. Tumor tissues from patients with advanced TNM stage and Fuhrman grade exhibited elevated ICN1 expression, which correlated positively with tumor size, Fuhrman grade, and tumor necrosis. Moreover, high ICN1 expression indicated poor overall survival and recurrence-free survival of patients with ccRCC. After backward elimination, ICN1 expression, as well as Fuhrman grade, Eastern Cooperative Oncology Group performance status, and TNM stage, was identified as an independent adverse prognostic factor for survival and recurrence. The predictive accuracy of well-established TNM, University of California Integrated Staging System, and Mayo Clinic stage, size, grade, and necrosis prognostic models was improved when ICN1 expression was added. Furthermore, a predictive nomogram was generated with identified independent prognosticators to assess patient survival at 5 years after surgery. Notch1 activation is a potential independent adverse prognostic biomarker for recurrence and survival of patients with ccRCC after nephrectomy. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urology 01/2015; 85(2). DOI:10.1016/j.urology.2014.10.022 · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review, we summarise the World Health Organization (WHO) classification of renal cell carcinomas (RCCs) alongside grading and staging systems. General applications of immunohistochemistry, cytogenetics, and cDNA microarrays were reviewed with their implications in tumour diagnosis, prognosis, and therapy.ResultsRCCs are classified according to the 2004 WHO classification, which defines three main histopathologic tumour subtypes with distinct clinical behaviour and underlying genetic defects: conventional (clear cell), papillary, and chromophobe RCC. Histopathologic classification and specific genetic mutations are crucial in distinguishing between familial and nonfamilial tumours. The most common four-tiered Fuhrman nuclear grade system is recommended for all types of RCC. Tumour grade is assigned according to the highest grade present; staging is assigned using the Union Internationale Contre le Cancer/American Joint Committee on Cancer 2002 classification.Conclusions Prognosis of patients with RCCs is most accurately predicted by TNM stage. Within stages, Fuhrman grade has a strong predictive value. Although not considered in nuclear grading, sarcomatoid dedifferentiation is a severely negative event for all RCC subtypes. Histologic subtypes of RCCs are not independent prognostic factors comparable with TNM stage and Fuhrman grade. Histologic coagulative tumour necrosis was an independent prognostic factor of outcome for clear cell and chromophobe RCC. Immunohistochemical panels including RCC marker, CD10, and KIT are now available for differential diagnosis of the distinct RCC subtypes. Genetic studies have improved understanding of subtypes, offering a promising approach for clinical diagnosis, prognosis, and possibly therapy. Urologists should be aware that currently many molecular analyses can be performed on RCCs, and when feasible, fresh samples sent to the pathologist.
    European Urology Supplements 06/2006; 5(8):573-579. DOI:10.1016/j.eursup.2006.03.005 · 3.37 Impact Factor